150 related articles for article (PubMed ID: 27313771)
1. Knockdown of cathepsin L sensitizes ovarian cancer cells to chemotherapy.
Zhang H; Zhang L; Wei L; Gao X; Tang LI; Gong W; Min NA; Zhang LI; Yuan Y
Oncol Lett; 2016 Jun; 11(6):4235-4239. PubMed ID: 27313771
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.
Sui H; Shi C; Yan Z; Wu M
Oncotarget; 2016 Jul; 7(29):45995-46001. PubMed ID: 27351223
[TBL] [Abstract][Full Text] [Related]
3. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.
Han ML; Zhao YF; Tan CH; Xiong YJ; Wang WJ; Wu F; Fei Y; Wang L; Liang ZQ
Acta Pharmacol Sin; 2016 Dec; 37(12):1606-1622. PubMed ID: 27840408
[TBL] [Abstract][Full Text] [Related]
5. A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.
Zhao YF; Han ML; Xiong YJ; Wang L; Fei Y; Shen X; Zhu Y; Liang ZQ
Acta Pharmacol Sin; 2018 Jun; 39(6):1034-1047. PubMed ID: 29219949
[TBL] [Abstract][Full Text] [Related]
6. Biological characteristics of Taxol‑resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53.
Liu Q; Sui R; Li R; Miao J; Liu J
Mol Med Rep; 2015 Feb; 11(2):1292-7. PubMed ID: 25351378
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin L-mediated resistance of paclitaxel and cisplatin is mediated by distinct regulatory mechanisms.
Zhao Y; Shen X; Zhu Y; Wang A; Xiong Y; Wang L; Fei Y; Wang Y; Wang W; Lin F; Liang Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):333. PubMed ID: 31370861
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin L is involved in proliferation and invasion of ovarian cancer cells.
Zhang L; Wei L; Shen G; He B; Gong W; Min N; Zhang L; Duan Y; Xie J; Luo H; Gao X
Mol Med Rep; 2015 Jan; 11(1):468-74. PubMed ID: 25333746
[TBL] [Abstract][Full Text] [Related]
10. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of high mobility group protein box-1 resensitizes ovarian cancer cells to carboplatin.
Shu W
Oncol Lett; 2018 Oct; 16(4):4586-4592. PubMed ID: 30214593
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
Cui F; Wang W; Wu D; He X; Wu J; Wang M
Clin Transl Oncol; 2016 Jul; 18(7):722-7. PubMed ID: 26474873
[TBL] [Abstract][Full Text] [Related]
13. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity.
Tanino T; Nawa A; Kondo E; Kikkawa F; Daikoku T; Tsurumi T; Luo C; Nishiyama Y; Takayanagi Y; Nishimori K; Ichida S; Wada T; Miki Y; Iwaki M
Pharm Res; 2007 Mar; 24(3):555-65. PubMed ID: 17245652
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer.
Fu Z; Wang C; Chen Y; Zhang X; Wang X; Xie X
Pathol Res Pract; 2019 Nov; 215(11):152625. PubMed ID: 31540773
[TBL] [Abstract][Full Text] [Related]
17. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin L is involved in proliferation and invasion of breast cancer cells.
Qin G; Cai Y; Long J; Zeng H; Xu W; Li Y; Liu M; Zhang H; He ZL; Chen WG
Neoplasma; 2016; 63(1):30-6. PubMed ID: 26639231
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
Tang J; Cao L; Yi H; Tang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
